Biopoin (epoetin theta)
- Region
- 🇪🇺 EU
- Active substance
- epoetin theta
- Company
- Teva GmbH
- Status
- Authorised
- Therapeutic area
- Kidney Failure, Chronic; Anemia; Cancer
- EU approval
- Fri 23 Oct 2009
- Application
- EMEA/H/C/001036
- ATC
- B03XA01
- Official record
- www.ema.europa.eu
Indication
Treatment of symptomatic anaemia associated with chronic renal failure in adult patients. Treatment of symptomatic anaemia in adult cancer patients with non-myeloid malignancies receiving chemotherapy.
Regulatory milestones
No milestones recorded in the last year.
Same substance in other markets
- 🇪🇺 Eporatio Authorised · Ratiopharm GmbH
- 🇪🇺 Ratioepo Application withdrawn · Ratiopharm GmbH
Follow Biopoin
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.